NCT07653555
Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP
Not Yet Recruiting
NAAges 1+InterventionalMayo ClinicInvestigator-initiated
~480 participants
Updated 2026-09-15 on ClinicalTrials.gov
What's tested:Cascade testingStandard of Care
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Genetic testing among first- and second-degree relatives within 12 months of index patient enrollment
Measured over 2 year
Conditions
NCT07653555
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mayo Clinic in Rochester
Rochester, Minnesotastudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Elisa J. Houwink, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age ≥ 18 years.
Confirmed FH diagnosis using Dutch Lipid Clinic Network criteria \*or\* genetic confirmation.
Identified through REP or Tapestry databases.
Able and willing to provide informed consent.
At least one eligible first- or second-degree relative.
Access to and active use of email (computer literacy requirement).
First- or second-degree relative of an enrolled index patient.
Age ≥ 1 year (minors require parental consent + assent).
Willing to participate and able to complete electronic consent (guardian-assisted if minor).
Access to and active use of email (guardian).
Exclusion
No confirmed FH diagnosis.
Insufficient clinical follow-up (\<5 years).
No identifiable or contactable relatives.
Prior participation in structured cascade testing.
Severe cognitive impairment preventing informed consent.
Prior participation in structured cascade testing.
Severe cognitive impairment preventing informed consent.
What this trial measures
- Genetic testing among first- and second-degree relatives within 12 months of index patient enrollment2 year
Defined as total number of relations to complete CLIA-certified FH test (LDLR, APOB, PCSK9, LDLRAP1) with result returned to the primary care research team.